SCIENTIFIC COMMITTEE

Chairman
Siegfried Kasper (Austria)

Co-Chairman
Stuart A. Montgomery (United Kingdom)

Scientific Advisers
C. Allgulander (Sweden), C.A. Altamura (Italy), C. Arango (Spain),
D. Baldwin (United Kingdom), M. Bauer (Germany), P. Boyer (Canada),
G. Burrows (Australia), G. B. Cassano (Italy), K. Demyttenaere (Belgium),
J. Den Boer (The Netherlands), T. Dinan (Ireland), E. Eriksson (Sweden),
N. Fineberg (United Kingdom), T. Higuchi (Japan), S. H. Kennedy (Canada),
J.P. Lépine (France), M. Maj (Italy), A.A. Mathé (Sweden), J. Mendlewicz (Belgium),
H.J. Moeller (Germany), S. Pallanti (Italy), G. Papadimitriou (Greece),
G. Papakostas (USA), Z. Rihmer (Hungary), A. F. Schatzberg (USA),
D.J. Stein (South Africa), T. Suppes (USA), E. Vieta (Spain),
L. Von Knorring (Sweden), D. Winkler (Austria),
S. Yamawaki (Japan), J. Zohar (Israel)

IMPORTANT ADDRESSES

Organizing Secretariat
PUBLI CREATIONS - Partner of AIM
74, Bd d’Italie - 98000 Monte-Carlo - Monaco
Ph. +377 97973555 - Fax +377 97973550
E-mail: ifmad@publiccreations.com
Website: www.ifmad.org

Forum Venue
Hôtel FAIRMONT
12, Av. des Spéluges
98000 Monaco
Tel. + 377 93506500
Dear IFMAD Forum Participants,

We are delighted to welcome you to Monaco on the occasion of the “9th IFMAD Forum” and we wish you a very successful meeting. We hope that you will find the time to discover or re-discover Monaco’s historical areas, gardens, shopping malls and museums.

Thank you for selecting the Principality of Monaco for your prestigious event.
Should you need any assistance during your stay, please do not hesitate to contact the Monaco Tourist Office.

Kindest regards.

Michel BOUQUIER
President Monaco Tourism
and Convention Authority

ACKNOWLEDGEMENT

The Organising Committee express their gratitude to the following Companies

LUNDBECK A/S
PIERRE FABRE
for their contribution as Sponsor of Symposia

PFIZER
as Sponsor to the Programme

WISEPRESS LTD
for their participation in the exhibition
The International Forum on Mood and Anxiety Disorders (IFMAD) will be held from 11 to 13 November 2009 in Monte-Carlo, Monaco.

The most useful feature about IFMAD meetings is that current clinical hot topics and new data are presented in a balanced format, adequately dissected and discussed in a collegial atmosphere, and digested over dinner. The meetings are always enjoyable and informative.

This year a large number of key areas are addressed such as questioning why pharmacological treatments are under attack, whether the new data in bipolar depression will shift the approach towards treatment, the increasing restrictions on prescribing medication for adolescents and elderly patients and a debate with a member of the CHMP on whether the EU is too restrictive in licensing medications for CNS. The new data on treatment resistant depression and the advances in PTSD will be challenged and the implications of new data on the potentially evolving role of atypicals in anxiety and depression will be discussed.

Along with the usual updates on new treatments in other areas this year’s IFMAD will be an efficient way of catching up with the latest developments.

We invite you to join us again in November 2009 to give you the opportunity to keep abreast of the latest advances in psychiatry. It will be our pleasure to welcome you in Monte-Carlo.

Siegfried Kasper, Chairman

Stuart A. Montgomery, Co-Chairman
<table>
<thead>
<tr>
<th>Time</th>
<th>Wednesday, November 11</th>
<th>Thursday, November 12</th>
<th>Friday, November 13</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00/10.30</td>
<td>Using the latest evidence to its full potential in the treatment of depression and anxiety</td>
<td>09.00/10.30 Bipolar Disorder - Myths and Evidence</td>
<td></td>
</tr>
<tr>
<td>10.30/11.00</td>
<td>Coffee break</td>
<td>10.30/11.00 Coffee break</td>
<td></td>
</tr>
<tr>
<td>11.00/12.30</td>
<td>Recent Advances in the Treatment of GAD</td>
<td>11.00/12.30 Psychopharmacology in the life span</td>
<td></td>
</tr>
<tr>
<td>12.30/13.30</td>
<td>Lunch</td>
<td>12.30/13.30 Lunch</td>
<td></td>
</tr>
<tr>
<td>13.30/15.00</td>
<td>Pharmacological Treatment under Attack</td>
<td>13.30/15.00 Future Developments in Depression and Anxiety</td>
<td></td>
</tr>
<tr>
<td>14.30/16.00</td>
<td>Difficulties in Treatment of Resistant Depression</td>
<td>15.00/16.00 Debate: Are we too restrictive in licensing CNS drugs in Europe?</td>
<td>15.00/16.30 New Focuses on treatment</td>
</tr>
<tr>
<td>16.00/16.30</td>
<td>Coffee break</td>
<td>16.00/16.30 Coffee break</td>
<td>16.30/16.45 End of meeting</td>
</tr>
<tr>
<td>16.00/18.00</td>
<td>Advances in Treating Post Traumatic Stress Disorder (PTSD)</td>
<td>15.00/16.00</td>
<td></td>
</tr>
<tr>
<td>18.00/19.00</td>
<td>Opening Ceremony</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.00/20.00</td>
<td>Update on the Psychiatric Department of the Princesse Grace Hospital in Monaco</td>
<td>16.30/18.00 Milnacipran: Recent Findings in Depression</td>
<td></td>
</tr>
</tbody>
</table>
SCIENTIFIC PROGRAMME

WEDNESDAY, 11 November 2009

14.30 - 16.00  **SO 01 - DIFFICULTIES IN TREATMENT OF RESISTANT DEPRESSION**

Chair: *D. Souery (Belgium)*

- **SO 0101** TRD - The concept, the staging and the predictors
  *Joseph Zohar (Israel)*

- **SO 0102** Response and Remission rates RN Treatment Resistant Depression: interim results from an open study of the efficacy of Escitalopram in Treatment Resistant Depression
  *Daniel Souery (Belgium)*

- **SO 0103** Management of TRD - *Stuart Montgomery (UK)*

16.00 - 16.30  **Coffee break**

16.30 - 18.00  **SO 02 - ADVANCES IN TREATING POST TRAUMATIC STRESS DISORDER (PTSD)**

Chair: *J. Davidson (USA)*

- **SO 0201** Shifting the focus towards preventing PTSD
  *Joseph Zohar (Israel)*

- **SO 0202** Pharmacological treatment of PTSD
  *Jonathan Davidson (USA)*

- **SO 0203** PTSD after the 2003 Iraq War: the UK story
  *Dominic Murphy (UK)*

18.00 - 19.00  **Opening Ceremony**

19.00 - 20.00  **Update on the Psychiatric Department of the Princesse Grace Hospital in Monaco**

(This session is held in French)

- Comment améliorer l’observance du traitement dans dépression - *Joséphine Loftus (Monaco)*

- Prise en charge de l’addictologie au CHPG
  *Ségolène Moulierac (Monaco)*

- Prise en charge extra-hospitalière à Monaco par l’unité mobile de PSY - *Céline Plasseraud (Monaco)*

- Place de l’équipe de psychiatrie de liaison au sein du CHPG de MONACO
  *Irène Cussac, Khaled Kammoun (Monaco)*
THURSDAY, 12 November 2009

09.00 - 10.30  SO 03 - USING THE LATEST EVIDENCE TO ITS FULL POTENTIAL IN THE TREATMENT OF DEPRESSION AND ANXIETY
Chair: S. Kasper (Austria)

SO 0301  Remission: achieving and sustaining the optimal outcome
Yoram Barak (Israel)

SO 0302  Anxiety - a predictor of treatment success in major depressive disorder?
Siegfried Kasper (Austria)

SO 0303  Findings solutions for late life depression
Rob Kok (The Netherlands)

Symposium sponsored by an unrestricted educational grant from H. Lundbeck A/S

10.30 - 11.00  Coffee break

11.00 - 12.30  SO 04 - RECENT ADVANCES IN THE TREATMENT OF GAD
Chair: D. Baldwin (UK)

SO 0401  Suicide and Anxiety
Zoltan Rihmer (Hungary)

SO 0402  Benzodiazepine and pregabalin in the Treatment of GAD
Jill Rasmussen (UK)

SO 0403  Antipsychotic drugs in the Treatment of GAD
David Baldwin (UK)

12.30 - 13.30  Lunch
13.30 - 15.00  **SO 05 - PHARMACOLOGICAL TREATMENT UNDER ATTACK**  
Chair: *K. Demyttenaere (Belgium)*  

SO 0501  Why are there so few new treatments  
*Filippo Drago (Italy)*  

SO 0502  Pharmacological treatment of depression under attack  
*Koen Demyttenaere (Belgium)*  

SO 0503  Of course antidepressants work and are they value for money?  
*Tim Bullock (UK)*  

15.00 - 16.00  **SO 06 - DEBATE: ARE WE TOO RESTRICTIVE IN LICENSING CNS DRUGS IN EUROPE?**  
Chair: *S. Kasper (Austria)*  

Pro:  *Stuart Montgomery (UK)*  
Contra: *Karl Broich (Germany)*  

16.00 - 16.30  **Coffee break**  

16.30 - 18.00  **SO 07 - MILNACIPRAN: RECENT FINDINGS IN DEPRESSION**  
Chair: *S. Montgomery (UK)*  

SO 0701  Milnacipran: a unique antidepressant  
*Siegfried Kasper (Austria)*  

SO 0702  Suicidality: the positive effect of milnacipran  
*Philippe Courtet (France)*  

SO 0703  Using flexible dosing with milnacipran and venlafaxine  
*Lucilla Mansuy (France)*  

SO 0704  Improvement of depressive and diabetic symptoms with milnacipran in co-morbid patients  
*Peter Hofmann (Austria)*  

*Symposium sponsored by an unrestricted educational grant from Pierre Fabre Medicaments*
FRIDAY, 13 November 2009

09.00 - 10.30   SO 08 - BIPOLAR DISORDER
MYTHS AND EVIDENCE
Chair: E. Vieta (Spain)

SO 0801  Are antidepressants useful in treating bipolar depression?
Eduard Vieta (Spain)

SO 0802  The role of atypical antipsychotics in treating bipolar
and unipolar depression
Hans Eriksson (Sweden)

SO 0803  Optimal maintenance treatment for bipolar disorder
Michael Bauer (Germany)

10.30 - 11.00   Coffee break

11.00 - 12.30   SO 09 - PSYCHOPHARMACOLOGY
IN THE LIFE SPAN
Chair: R. Buller (Germany)

SO 0901  ADHD over the life span:
clinical and neurobiological aspects
Jan K. Buitelaar (The Netherlands)

SO 0902  Genetics of ADHD
Johannes Thome (UK)

SO 0903  Are restrictions on psychotropics in adolescents
and the elderly justified?
Raimond Buller (Germany)

12.30 - 13.30   Lunch
13.30 - 15.00  **SO 10 - FUTURE DEVELOPMENTS IN DEPRESSION AND ANXIETY**
Chair: *A. Mathé (Switzerland)*

SO 1001  Animal models for depression and anxiety - are they sufficiently predictive?
*A. Mathé (Switzerland)*

SO 1002  Possible influence of 5HTTLPR polymorphism on treatment
*Alessandro Serretti (Italy)*

SO 1003  Update on treatment of depression and anxiety in schizophrenia
*Patrice Boyer (France)*

15.00 - 16.30  **SO 11 - NEW FOCUSES ON TREATMENT**
Chair: *Z. Rihmer (Hungary)*

SO 1101  Hormonal or serotonergic treatments for PMDD
*Elias Eriksson (Sweden)*

SO 1102  Treating insomnia in comorbid disorders
*Malcom Lader (UK)*

SO 1103  Managing the risk of suicide in depression
*Zoltan Rihmer (Hungary)*

16.30 - 16.45  **End of meeting**
P 01. Diabetes mellitus and co-morbid depression: treatment with Milnacipran results in significant improvement of both diseases
H. Abrahamian¹, P. Hofmann², R. Prager¹, H. Toplak³
¹General Hospital Hietzing with Neurological Center Rosenhugel and Karl Landsteiner Institute for Metabolic Diseases and Nephrology, Vienna, Austria; ²Department of Psychiatry, University Hospital, Graz, Austria; ³Department of Internal Medicine, University Hospital, Graz, Austria

P 02. Comorbidity of anxiety and depression with dermatological conditions
A. Afkham Ebrahimi¹, SH Afkham Ebrahimi²
¹Iran University of Medical Sciences, Tehran, Iran; ²Tehran University, Tehran, Iran

P 03. The effect of Milnacipran on suicidality in patients with mild to moderate depressive disorder
A. Avedisova, V. Borodin, K. Zakharova, A. Aldushin
Department of Borderline Psychiatry, FGU State Scientific Research Center of Social and Forensic Psychiatry «V.P. Serbsky», Moscow, Russia

P 04. Sustained response with adjunctive extended release quetiapine fumarate (quetiapine XR): pooled efficacy analysis in major depressive disorder (MDD)
M. Bauer¹, E. Vieta², W. Earley ³, J. Szamosi⁴, H.A. Eriksson⁴
¹University Hospital Carl Gustav Carus, Dresden, Germany; ²Institute of Clinical Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain; ³AstraZeneca Pharmaceuticals, Wilmington, USA; ⁴AstraZeneca R&D, Södertälje, Sweden

P 05. Heterogeneity of depressive disturbances in alcoholism with co-morbid organic mood disorder: possibilities of paroxetine
N. Bokhan
Mental Health Research Institute, Tomsk, Russia

P 06. Psychological determinants of anxiousness in population living in zone of ecological risk
T. Bokhan
Tomsk State University, Tomsk, Russia

P 07. The epidemiology of depression and suicidal behaviour in Slovakia
D. Breznoscakova¹, J. Dragasek²
¹University of P. J. Safarik, School of Medicine, 1st Dept. of Psychiatry, Kosice, Slovak Republic; ²Faculty Hospital of L. Pasteur, 1st Dept. of Psychiatry, Kosice, Slovak Republic

P 08. Vagus nerve stimulation in treatment-resistant depression: an Italian case-series
M. Buoli, L. Oldani, M. Serati, A. Albano, M. Ciabatti, B. Dell’Osso, A.C. Altamura
Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Department of Psychiatry, Milan, Italy
P 09. Psychiatric comorbidity in bipolar disorder: which associations prevail in different age groups  
M. Buoli, S. Bortolussi, L. Oldani, M.C. Palazzo, G. Camuri, B. Benatti, B. Dell’Oso, A.C. Altamura  
Department of Psychiatry, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy

P 10. Effects of duloxetine adjunctive to extended-release quetiapine treatment in bipolar I mixed - an open label study  
G. Callista1, E. Daneluzzo2  
1U.O. Psichiatria ASL Teramo, Giulianova (TE), Italy; 2SPDC ASLCN2, Alba (CN), Italy

P 11. Repeated transcranial magnetic stimulation (rTMS) treatment for refractory obsessive-compulsive disorder  
J. Chae, S. Lee, J. Jeong, H. Seo  
Dept. of Psychiatry, The Catholic University of Korea, Seoul, South Korea

P 12. Early remission as predictor of good outcome in the prognosis of a major depressive episode: its neurobiological implications  
E. Alvarez1, I. Gilaberte2, L. Caballero3, E. Baca3, M. Roca4, M. Casillas2, P. Garcia de Polavieja2, A. Gervas2, A. Valladares2, B. Yruretagoyena2, A. Ciudad2  
1Department of Psychiatry, Hospital Santa Creu i Sant Pau., Barcelona, Spain; 2Lilly Clinical Research Department, Alcobendas, Spain; 3Department of Psychiatry, Hospital Puerta de Hierro, Madrid, Spain; 4Department of Psychiatry, Hospital Joan March, Palma de Mallorca, Spain

P 13. Effects of milnacipran, duloxetine and pregabalin on the changes in BDNF levels elicited by repeated restraint stress in the rat  
C. Cosi1, L. Bardin2, M. Marien1, S. Boyer1, R. Deportere2, A. Newmann-Tancredi2  
1Division of Neurobiology 1, Institut de Recherche Pierre Fabre, Castres, France; 2Division of Neurobiology 2, Institut de Recherche Pierre Fabre, Castres, France

P 14. Differentiated information on antidepressants at hospital discharge: the GIPPOZ-study  
F. Desplenter1, G. Laekeman1, Vza Psychiatry2, S. Simoens1  
1Katholieke Universiteit Leuven, Research Centre for Pharmaceutical Care and Pharmaco-economics, Leuven, Belgium; 2Psychiatric Hospital Sint Jan, Eeklo, Belgium

P 15. Discharge management for patients in Flemish psychiatric hospitals  
F. Desplenter1, G. Laekeman1, P. Moons2, S. Simoens1  
1Katholieke Universiteit Leuven, Research Centre for Pharmaceutical Care and Pharmaco-economics, Leuven, Belgium; 2Katholieke Universiteit Leuven, Centre for Health Services and Nursing Research, Leuven, Belgium
P 16. Quetiapine in the treatment of bipolar depression: improvements in quality of life and functioning in four randomized, placebo-controlled trials
L. Fautrao, U. Gustafsson, B. Paulsson, H. Eriksson
AstraZeneca R&D, Södertälje, Sweden

P 17. Antidepressant-like effect of SCH-23390 in combination with sub-active dose of 17β-estradiol in ovariectomized rats
J. Fedotova, N. Ordayn
I.P. Pavlov Institute of Physiology RASci., St. Petersburg, Russia

P 18. Pharmaceutical care for patients with depression: a survey of pharmacists’ attitudes, current practices and barriers
V. Foulon1, S. Liekens1, M. Wouters1, G. Scheerder2, G. Laekeman1, T. Smits3
1Research Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, K.U. Leuven, Leuven, Belgium; 2LUCAS, Centre for Research and Consultancy, Leuven, Belgium; 3European Centre for Ethics, Leuven, Belgium

P 19. Impact of regulatory safety warnings on the use of antidepressants among children and adolescents in Finland
V. Foulon1, A. Svala2, I. Koskinen3, T. Chen4, I. Saastamoinen5, S. Bell2,4,5,6
1Research Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, K.U. Leuven, Leuven, Belgium; 2Division of Social Pharmacy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland; 3Research Department, Social Insurance Institution, Helsinki, Finland; 4Faculty of Pharmacy, University of Sydney, Sydney, Australia; 5Department of Pharmacology and Toxicology, University of Kuopio, Kuopio, Finland; 6Kuopio Research Centre of Geriatric Care, University of Kuopio, Kuopio, Finland

P 20. Depression is a major cause of internet addiction in adolescents and young adults; 2 years experience in an internet addiction clinic
J. Ha1, J. Yu2, D.H. Park3, W. Lim4
1Department of Psychiatry, School of Medicine, Konkuk University, Seoul, South Korea; 2Department of Psychiatry, College of Medicine, Ewha Womans University, Seoul, South Korea

P 21. Natural killer T cell in depressed patients treated with SSRIs
S. Han, Y.H. Jeon, E.J. Park
Department of Psychiatry, Incheon St. Mary’s Hospital, The Catholic University of Korea, Incheon, South Korea

P 22. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich antidepressant response signature project
J. Hennings1, T. Owashi2, E. Binder1, S. Horstmann1, A. Menke1, S. Kloiber1, T. Dose1, B. Wollweber1, D. Spieler1, T. Messer2, H. Künzel4, T. Biener4, T. Pollmächer4, H. Pfister1, T. Nickel1, A. Sonntag1, M. Uhr1, M. Ising1, F. Holsboer1, S. Lucae1
1Max Planck Institute of Psychiatry, Munich, Germany; 2Department of Psychiatry, Showa University Fujigaoka Hospital, Yokohama, Japan; 3Bezirkskrankenhaus Augsburg, Augsburg, Germany; 4Klinikum Ingolstadt, Ingolstadt, Germany
P 23. The TREK-1 potassium channel as a new antidepressant target  
M. Borsotto¹, M. Blondeau¹, G. Lucas², N. Guy¹, M. El-Yacoubi.³, F. Noble⁴,  
C. Widmann¹, J.M. Vaugeois³, M. Lazdunski.¹, C. Heurteaux¹  
¹IPMC CNRS, Valbonne, France; ²Centre Recherche F. Seguin, Dpt Psychiatrie, Montréal, Canada;  
³Laboratoire de Neuropharmacologie, Lyon 1, Lyon, France; ⁴DSPB Paris 5, Paris, France.

P 24. Plasma serotonin level of Vietnam war veterans with posttraumatic stress disorder and symptom severity  
S. Hoon Kang, M. Yong Chung,  
Department of Neuropsychiatry, Seoul Veterans Hospital, South Korea

P 25. Depression and anxiety in doctors of medicine  
N. Ilic, V. Ilic  
Health Center-Nis, Nis, Serbia

P 26. The relationship of sleep duration with suicide ideas in depressed individuals.  
Weon Jeong Lim¹, Yu Jin Lee²  
¹Department of psychiatry, Ewha Womans University Hospital, Seoul, Republic of Korea;  
²Department of psychiatry, Gachon Medical School Gil Hospital, Incheon, Republic of Korea

P 27. Karolinska Interpersonal Violence (KIV) rating in suicide attempters  
Jussi Jokinen, Marie Åsberg, Peter Nordström  
Department of Clinical Neuroscience/Psychiatry, Karolinska Institutet, Stockholm, Sweden

P 28. Survival rates of maintenance treatment with Venlafaxine ER in patients with somatic symptoms  
T. Jun, W. Bahk, H. Moon  
Department of Psychiatry, College of Medicine, the Catholic University of Korea, Seoul, South Korea

P 29. Bipolar diathesis of unipolar treatment resistant depression  
T. Jun, W. Bahk, H. Moon  
Department of Psychiatry, College of Medicine, the Catholic University of Korea, Seoul, South Korea

P 30. Comparison of serum and urine analyses in CYP2D6 phenotyping for psychiatric purposes  
J. Jurica¹, R. Bartecek², O. Zendulka¹, T. Kasparek², A. Z ourkova², A. Sulcova¹  
¹Masaryk University, Faculty of Medicine, Dept. of Pharmacology, Brno, Czech Republic; ²Dept. of Psychiatry of Faculty Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic

P 31. Relationship between opium abuse and the severity of depression in type II diabetic patients  
A. Kord Valeshabad¹², Z. Sepehrmanesh³, H. Sarmast³  
¹Tehran University of Medical Sciences (TUMS) - Student’s Scientific Research Center (SSRC), Tehran, Iran; ²National Foundation of Elites, Tehran, Iran, ³Kashan University of Medical Sciences - Department of endocrinology, Kashan, Iran
P 32. Escitalopram versus SNRIs as second-line treatment
Raymond W. Lam M.D¹, Sara Larsson Länn Ph.D², Nicolas Despiégel M.Sc.³
¹Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada; ²H Lundbeck A/S, Copenhagen, Denmark; ³Lundbeck SAS, Paris, France

P 33. Studying the impact of medication counselling for patients starting a treatment with antidepressant drugs
S. Liekens ¹, V. Foulon ¹, T. Smits ², G. Laekeman ¹
¹K.U.Leuven - Department of Pharmaceutical Sciences, Research centre for Pharmaceutical care and Pharmaco-economics, Leuven, Belgium; ²K.U.Leuven - European Centre for Ethics, Leuven, Belgium

P 34. Piracetam enhances psychostimulant methamphetamine effects and development of behavioural sensitization to it in mice
A. Machalova, K. Slaïs, D. Vrskova, A. Sulcova
Masaryk University, Faculty of Medicine - Department of Pharmacology, Brno, Czech Republic

P 35. The efficacy of quetiapine monotherapy in bipolar depression: combined data from the BOLDER and EMBOLDEN studies
J. Calabrese⁴, K.A.N. Macritchie², A.H. Young², U. Gustafsson³, B. Paulsson³
¹University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, USA; ²University of British Columbia, Vancouver, Canada; ³AstraZeneca R&D, Södertälje, Sweden

P 36. The efficacy of quetiapine monotherapy in bipolar II depression: combined data from the BOLDER and EMBOLDEN studies
A.H. Young¹, K.A.N. Macritchie¹, J. Calabrese², U. Gustafsson³, B. Paulsson³, G.S. Malhi⁴, D.J. Bond 1, I.N. Ferrier⁵
¹University of British Columbia, Vancouver, Canada; ²University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, USA; ³AstraZeneca R&D, Södertälje, Sweden; ⁴CADE Clinic, Discipline of Psychological Medicine, University of Sydney, Sydney, Australia; ⁵Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK

P 37. Duloxetine in the prevention of depressive recurrence: outcomes from the open-label acute and continuation study phases
M. Mancini¹, D. Perahia²,³, M. Spann⁴, F. Wang⁴, D. Walker⁴, C. Yang⁴, M. Detke⁵,⁶,⁷
¹Eli Lilly Italia SpA, Florence, Italy; ²Lilly Research Centre, Windslesham, UK; ³The Gordon Hospital, London, UK; ⁴Lilly Research Laboratories, Indianapolis, IN, USA ⁵MedAvante, Hamilton, NJ, USA; ⁶McLean Hospital/Harvard Medical School, Boston, MA, USA; ⁷Indiana University School of Medicine, Indianapolis, IN, USA

P 38. Review of prolactin levels in patients taking duloxetine
A.L. Montejo¹, A. Crucitti², D. G.S. Perahia²,³, Q. Zhang¹, Fujun Wang⁵, D. J. Walker⁴, M. Mancini⁵, S. Brecht⁷
¹Hospital Universitario de Salamanca, Salamanca, Spain; ²Lilly Research Centre, Windslesham, UK; ³The Gordon Hospital, London, UK; ⁴Lilly Research Laboratories, Indianapolis, Indiana, USA; ⁵Lilly USA, LLC, Indianapolis, Indiana, USA; ⁶Eli Lilly Italia SpA, Florence, Italy; ⁷Boehringer Ingelheim GmbH, Ingelheim, Germany
P 39. Extended release quetiapine fumarate monotherapy in patients with MDD: a pooled analysis of sustained response data from studies D1448C00001 and D1448C00002
S. Montgomery1, R.S. McIntyre2, J. Szamosi3, H.A. Eriksson3, W. Earley4
1Imperial College School of Medicine, University of London, London, UK; 2University Health Network, Toronto, Canada; 3AstraZeneca R&D, Södertälje, Sweden; 4AstraZeneca Pharmaceuticals, Wilmington, USA

P 40. Efficacy of extended release quetiapine fumarate: pooled analysis in patients with severe generalised anxiety disorder
S. Montgomery1, J. Locklear2, H. Svedsäter3, H. Eriksson3
1Imperial College School of Medicine, University of London, London, UK; 2AstraZeneca Pharmaceuticals, Wilmington, USA; 3AstraZeneca R&D, Mölndal, Sweden

P 41. Thyroid hormones affect recovery from depression during antidepressant treatment
C. Pae1,2
1Department of Psychiatry, Holy Family Hospital, The Catholic University of Korea College of Medicine, Bucheon, South Korea; 2Department of Psychiatry and Behavioral Medicines, Duke University Medical Center, Durham, USA

P 42. Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study
C. Pae1,2
1Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, South Korea; 2Department of Psychiatry and Behavioural Medicines, Duke University Medical Center, Durham, USA

P 43. Adherence to antidepressant treatment in Korea; an analysis of national insurance data
J. Paik1, K. Kim2, S. Lee3, W. Lim3, N. Kim4
1Kyunghee university medical center, Seoul, South Korea; 2Research & development Center, Health Assurance Review and Assessment Agency, Seoul, South Korea; 3Ehwa universidy college of medicine, Seoul, South Korea; 4Donguk University college of medicine, Kyungju, South Korea

P 44. Efficacy and tolerability of escitalopram in patients suffering from depression with or without comorbid disorders
A. Kodounis1, S. Stamouli2, D. Vlisidis3, A. Karavatos4, E. Papalexi5, I.A. Parashos6
1251 Airforce General Hospital of Athens, Department of Neurology, Athens, Greece; 2University of Athens Eginition Hospital, 1st Psychiatric Dept, Athens, Greece; 3Asklipio General Hospital of Voula, Athens, Greece; 4Papageorgiou Regional General Hospital of Thessalonica, Dept of Neurology, Thessalonica, Greece; 5Lundbeck Hellas S.A., Athens, Greece

P 45. Social anxiety symptoms and other phobic symptoms in a sample of alcohol dependent individuals
T. Paparrigopoulos1, E. Tzavellas2, D. Karaiskos3, I. Liappas4
1Eginition Hospital, University of Athens, Athens, Greece; 2Eginition Hospital, University of Athens, Athens, Greece; 3Eginition Hospital, University of Athens, Athens, Greece; 4Eginition Hospital, University of Athens, Athens, Greece
P 46. Are old-old patients with MDD more likely to relapse than the young-old after open label treatment with escitalopram?

C. Katona¹, C.G. Lyketsos², M. Steinberg², S. Qureshi³, E. Weiller³, P. Gorwood⁴
¹Dept Mental Health Sciences, University College London, UK; ²Department of Psychiatry, School of Medicine, Johns Hopkins University and Johns Hopkins Bayview Medical Center, Baltimore, MD, USA; ³H. Lundbeck A/S, Copenhagen, Denmark; ⁴INSERM U894, Sainte-Anne Hospital, Paris, France

P 47. Effects of new derivatives from phencyclidine on anxiety behaviours in adult male wistar rats

¹Jalal Solati, ²Abbas Ahmadi, ³Aliakbar Salari
¹Department of Biology, Faculty of Science, Islamic Azad University, Karaj branch, Karaj, Iran; ²Department of Chemistry, Faculty of Science, Islamic Azad University, Karaj branch, Karaj, Iran; ³Department of Biology, Faculty of Science, Islamic Azad University, North Tehran branch, Tehran, Iran

P 48. Psychosocial factors of postnatal depression. A longitudinal study

M. Serrano, M. Gili, N. Bauza, M. Vives, S. Monzon, M. Roca
University of Balearic Islands. Institut Universitari d’Investigació en Ciències de la Salut, Palma de Mallorca, Spain

P 49. Life events and social support during pregnancy: relationship to depressive symptoms in the immediate postpartum

M. Serrano¹, N. Bauza¹, M. Gili¹, S. Monzon¹, M. Vives¹, M.J. Martin-Vazquez², M. Roca¹
¹University of Balearic Islands. Institut Universitari d’Investigació en Ciències de la Salut, Palma de Mallorca, Spain; ²Rodríguez Lafora Hospital, Madrid, Spain

P 50. Efficacy of extended release quetiapine fumarate (quetiapine XR) in patients with severe major depressive disorder (MDD)

H. Svedäter¹, M. Thase², J. Locklear³, C. Datto³
¹AstraZeneca R&D, Mölndal, Sweden; ²Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, USA; ³AstraZeneca Pharmaceuticals, Wilmington, USA

P 51. Effects of extended release quetiapine fumarate (Quetiapine XR) on patient-reported outcomes in patients with generalised anxiety disorder (GAD)

H. Svedäter¹, J. Endicott², J. Locklear³
¹AstraZeneca R&D, Mölndal, Sweden; ²Department of Psychiatry, Columbia University, New York, USA; ³AstraZeneca Pharmaceuticals, Wilmington, USA

P 52. Staging of formation of co-morbidity of anxiety and depressive disorders as a factor determining the therapeutic strategy

S.N. Vasilyeva, G.G. Simutkin
Mental Health Research Institute, Tomsk, Russia
P 53. Maintenance treatment with quetiapine added to either lithium or divalproex in bipolar I disorder  
**E. Vieta¹, T. Suppes², U. Gustafsson³, B. Paulsson³**  
¹Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBER-SAM, Barcelona, Spain; ²Department of Psychiatry and Behavioral Sciences, Stanford Medical Center and VA Palo Alto Health Care System, Palo Alto, USA; ³AstraZeneca R&D, Södertälje, Sweden

P 54. Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder  
**E. Vieta¹, T. Suppes², U. Gustafsson³, P. Paulsson³**  
¹Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBER-SAM, Barcelona, Spain; ²Department of Psychiatry and Behavioral Sciences, Stanford Medical Center and VA Palo Alto Health Care System, Palo Alto, USA; ³AstraZeneca R&D, Södertälje, Sweden

P 55. Extended release quetiapine fumarate (quetiapine XR) in acute and maintenance studies in major depressive disorder (MDD): suicidality data  
**R. Weisler¹, S.A. Montgomery², H.A. Eriksson³, J. Szamosi³**  
¹University of North Carolina at Chapel Hill, Duke University Medical Center, Durham, USA; ²Imperial College School of Medicine, University of London, London, UK; ³AstraZeneca R&D, Södertälje, Sweden

P 56. Novel selective anxiolytic afobazol prevents stress-induced decrease of benzodiazepine binding  
**M.A. Yarkova, K. Chekina, S.B. Seredenin**  
Zakusov’s Research Institute of Pharmacology of RAMS, Moscow, Russia

P 57. Is depression a potential risk factor of metabolic syndrome in women?  
**D. Yoon**  
Seoul National University Hospital, Gangnam Center, Seoul, South Korea

P 58. Transcranial direct current stimulation (TDCS) in patients with major depressive episode  
**S. Zanoni¹, F. Castellano¹, N. D’urso¹, C. Dobre¹, B. Benatti¹, C. Arici¹, R. Ferrucci², M. Vergari², B. Dell’osso², A. Priori², A.C. Altamura¹**  
¹Department of Psychiatry, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, Italy; ²Centro Clinico per Neuronanotecnologie e la Neurostimolazione, Fond. IRCCS Osp. Maggiore Policlinico Dip Sc.Neurologiche, Milan, Italy
SCIENTIFIC INFORMATION

• Audio-Visual Facilities
   Equipment for computerised Power Point presentations is provided during the scientific sessions. CD-Rom or USB key for Power Point presentations can be tested prior to presentation in the Multimedia Slide Center. CD-Rom or USB key must be handed over to the Multimedia Slide Center technicians at least forty minutes before the beginning of the sessions and must be collected directly by the speakers at the end of the session.
   It is essential for the smooth running of the sessions that all the speakers hand in their Power Point presentation in due time.

• European Accreditation
   15 European UEMS (European Union of Medical Specialists) credits have been recognized for this Forum.

• Certificate of Attendance
   A certificate of attendance is provided, on request, at the registration desk on the last day of the Forum.

GENERAL INFORMATION

The “9th International Forum on Mood and Anxiety Disorders” is held at the Fairmont Hotel from 11-13 November 2009.

Admission
   The participant’s name badge is provided at the registration desk. All participants are requested to wear the badge throughout the congress. Only badge holders are admitted to the appropriate sessions, exhibition and social events.

Electricity
   The standard voltage in Monaco is 220 V.

Insurance
   The Congress organizers cannot accept liability for personal injuries sustained, or for loss or damage to property belonging to Congress participants, either during or as a result of the Congress. Registration does not include insurance. It is strongly recommended that you take an insurance policy of your choice as you register for the Congress and book your travel.
General Information

Language
The official language of the Congress is English. No simultaneous translation is provided.

Secretariat
The secretariat desk will open on Wednesday, November 11 and stay open all through the Forum as follows:

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday, Nov 11</td>
<td>12.00 - 20.00</td>
</tr>
<tr>
<td>Thursday, Nov 12</td>
<td>08.15 - 18.00</td>
</tr>
<tr>
<td>Friday, Nov 13</td>
<td>08.15 - 16.30</td>
</tr>
</tbody>
</table>

What to do in Monaco

Sites and attractions
Situated in the far south-east corner of France, the Principality of Monaco stretches along a narrow four kilometres strip of coast, along the Mediterranean Sea, at the foot of the Southern Alpes. The Principality has many interesting attractions: the Exotic Gardens, the Japanese Gardens situated right alongside the Mediterranean, and also the tourist train which will take you to explore the streets of Monaco. Visit the Old town where you can discover, in the narrow medieval alleyways, the Picturesque Place of Saint Nicolas and placette Bosio, the Cathedral, the Prince’s Palace and the Changing of the Guards which takes place every day at 11.55.

Museums
- The Oceanographic Museum dedicated to Marine science and rare species of fish.
- The Wax museum depicting the history of Monaco’s princes and scenes from the Grimaldi dynasty.
- The Exhibition of H.S.H. the Prince of Monaco’s private collection of classic cars: a collection of around 100 vehicles of all ages.
- The Naval Museum displaying over 180 models of famous boats.
- The Museum of Prehistoric Anthropology with its collection of human and extinct animal remains from the archeological excavations of the region.
The 10th International Forum on Mood and Anxiety Disorders will be held in Vienna, Austria from 17-19 November 2010.
Cipralex - the power to tackle depression at its core

Presentation: “Cipralex”. Tablets containing 5, 10, 15 or 20 mg escitalopram (as oxalate).

Indications: Major depression. Generalised anxiety disorder. Panic disorder. Social anxiety disorder. Obsessive compulsive disorder. Dosage: Usual dose is 10 mg daily. Maximum dose 20 mg daily. In elderly (>65 years), in panic disorder patients and in patients with reduced hepatic function an initial dose of 5 mg daily is recommended. Caution in patients with severely reduced renal function. Not recommended in children and adolescents (<18 years). When stopping treatment the dose should be gradually reduced over a period of one or two weeks.

Contraindications: Hypersensivity to escitalopram. Concomitant treatment with MAOIs. Pregnancy and lactation: Careful consideration prior to use in pregnant women. Breast-feeding women should not be treated.

Precautions: The special warnings and precautions which apply to the class of SSRIs.

Drug interactions: MAOIs, serotonergic drugs, drugs lowering the seizure threshold, lithium tryptophan, St. John’s Wort, anticoagulants, drugs metabolised mainly by enzymes CYP 2D6 or 2C19. Adverse events: Most frequent during the first or second week, very common is nausea, less frequent is adverse events comprising to the SSRI class. Overdosage: Doses between 400 mg and 800 mg of escitalopram alone have been taken without any severe symptoms. Consult full prescribing information before prescribing. H. Lundbeck A/S, Copenhagen, Denmark.

Date of preparation: May 2009